Lisata Therapeutics, Inc.
LSTA
$2.49
$0.010.40%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 1.00M | 1.00M | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.00M | 1.00M | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 1.00M | 1.00M | -- | -- | -- |
| SG&A Expenses | 11.96M | 12.08M | 12.09M | 11.88M | 12.67M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 22.66M | 23.41M | 23.49M | 24.11M | 25.47M |
| Operating Income | -21.66M | -22.41M | -23.49M | -24.11M | -25.47M |
| Income Before Tax | -20.27M | -20.78M | -21.54M | -21.87M | -23.18M |
| Income Tax Expenses | -962.00K | -798.00K | -798.00K | -798.00K | -3.13M |
| Earnings from Continuing Operations | -19.31 | -19.99 | -20.74 | -21.07 | -20.05 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -19.31M | -19.99M | -20.74M | -21.07M | -20.05M |
| EBIT | -21.66M | -22.41M | -23.49M | -24.11M | -25.47M |
| EBITDA | -21.48M | -22.24M | -23.31M | -23.93M | -25.28M |
| EPS Basic | -2.30 | -2.40 | -2.51 | -2.56 | -2.46 |
| Normalized Basic EPS | -1.52 | -1.57 | -1.64 | -1.67 | -1.79 |
| EPS Diluted | -2.30 | -2.40 | -2.51 | -2.57 | -2.46 |
| Normalized Diluted EPS | -1.52 | -1.57 | -1.64 | -1.67 | -1.79 |
| Average Basic Shares Outstanding | 33.63M | 33.32M | 33.07M | 32.89M | 32.60M |
| Average Diluted Shares Outstanding | 33.63M | 33.32M | 33.07M | 32.89M | 32.60M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |